First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Under the new initiative, each company takes on a defined role across the recycling chain
For the full year, standalone gross revenue crossed Rs. 1,700 crore
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
Subscribe To Our Newsletter & Stay Updated
